

Review on Ovarian Cancer, Histology , Pathology and Surgery

**Chaugule Rumana, A. Rajjak, Wavhal Payal, Priyanka Dhumal, Khandagle Prathamesh
Vide Rohan, Asst. Prof. Mr. Tambe S.E**
Samarth Collage of Pharmacy, Belhe, Pune, India

Abstract: *Epithelial ovarian cancer is the second most common cause of death among all gynecological cancers. Treatment is difficult because almost 75% of patients are diagnosed at an advanced stage. First-line treatment with aggressive cytoreduction and adjuvant therapy determines outcome. This article reviews the epidemiology, risk factors, pathophysiology, and histopathology of ovarian cancer and highlights the role of the team in the treatment of this disease and discusses some important issues that will impact patients with this disease in the future. Treatment options and follow-up.*

Keywords: ovarian cancer, histology, epidemiology.

REFERENCES

- [1]. Oswald, A. J. & Gourley, C. Low-grade epithelial ovarian cancer: a number of distinct clinical entities? *Curr. Opin. Oncol.* 27, 412–419 (2015).
- [2]. Groen, R. S., Gershenson, D. M. & Fader, A. N. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. *Gynecol. Oncol.* 136, 373–383 (2015).
- [3]. Mangili, G. et al. Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. *Gynecol. Oncol.* 126, 403–407 (2012).
- [4]. Callegaro-Filho, D. et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases. *Gynecol. Oncol.* 140, 53–57 (2016)
- [5]. Kurman, R. J., Carcangiu, M. L., Herrinton, C. S. & Young, R. H. (eds) WHO Classification of Tumours Female Reproductive Organs (IARC, 2014).
- [6]. Menon, U. et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. *J. Clin. Oncol.* 33, 2062–2071 (2015).
- [7]. Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet* 387, 945–956 (2016).
- [8]. Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III Trial of the Gynecologic Cancer Intergroup. *J. Clin. Oncol.* 27, 1419–1425 (2009).
- [9]. du Bois, A. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J. Natl Cancer Inst.* 95, 1320–1329 (2003).
- [10]. Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J. Clin. Oncol.* 21, 3194–3200 (2003)
- [11]. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA A Cancer J. Clin.* 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- [12]. Doll, K.M.; Rademaker, A.; Sosa, J.A. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. *JAMA Surg.* 2018, 153, 588–589. [Google Scholar] [CrossRef] [PubMed]
- [13]. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. *CA A Cancer J. Clin.* 2018, 68, 7–30. [Google Scholar] [CrossRef] [PubMed]

- [14]. Jelovac, D.; Armstrong, D.K. Recent progress in the diagnosis and treatment of ovarian cancer. *CA A Cancer J. Clin.* 2011, 61, 183–203. [Google Scholar] [CrossRef]
- [15]. Elzakkers, J.C.J.; van der Aa, M.A.; van Altena, A.M.; de Hullu, J.A.; Harmsen, M.G. Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. *Gynecol. Oncol.* 2019, 155, 213–219. [Google Scholar] [CrossRef]
- [16]. Cress, R.D.; Chen, Y.S.; Morris, C.R.; Petersen, M.; Leiserowitz, G.S. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. *Obstet. Gynecol.* 2015, 126, 491–497. [Google Scholar] [CrossRef]
- [17]. Atallah, G.A.; Abd Aziz, N.H.; Teik, C.K.; Shafiee, M.N.; Kampan, N.C. New Predictive Biomarkers for Ovarian Cancer. *Diagnostics* 2021, 11, 465. [Google Scholar] [CrossRef]
- [18]. Cheng, B.; Lu, W.; Xiaoyun, W.; YaXia, C.; Xie, X. Extra-abdominal metastases from epithelial ovarian carcinoma: An analysis of 20 cases. *Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc.* 2009, 19, 611–614. [Google Scholar] [CrossRef]
- [19]. Peres, L.C.; Cushing-Haugen, K.L.; Kobel, M.; Harris, H.R.; Berchuck, A.; Rossing, M.A.; Schildkraut, J.M.; Doherty, J.A. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. *J. Natl. Cancer Inst.* 2019, 111, 60–68. [Google Scholar] [CrossRef] [Green Version]
- [20]. Guth, U.; Huang, D.J.; Bauer, G.; Stieger, M.; Wight, E.; Singer, G. Metastatic patterns at autopsy in patients with ovarian carcinoma. *Cancer* 2007, 110, 1272–1280. [Google Scholar] [CrossRef]
- [21]. Marchetti, C.; Ferrandina, G.; Cormio, G.; Gambino, A.; Cecere, S.; Lorusso, D.; De Giorgi, U.; Bogliolo, S.; Fagotti, A.; Mammoliti, S.; et al. Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). *Gynecol. Oncol.* 2016, 143, 532–538. [Google Scholar] [CrossRef]
- [22]. Gasparri, M.L.; Grandi, G.; Bolla, D.; Gloor, B.; Imboden, S.; Panici, P.B.; Mueller, M.D.; Papadia, A. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. *J. Cancer Res. Clin. Oncol.* 2016, 142, 1509–1520. [Google Scholar] [CrossRef]
- [23]. Yu, Z.; Pestell, T.G.; Lisanti, M.P.; Pestell, R.G. Cancer stem cells. *Int. J. Biochem. Cell Biol.* 2012, 44, 2144–2151. [Google Scholar] [CrossRef] [Green Version]
- [24]. Colak, S.; Medema, J.P. Cancer stem cells--important players in tumor therapy resistance. *FEBS J.* 2014, 281, 4779–4791. [Google Scholar] [CrossRef]
- [25]. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA A Cancer J. Clin.* 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]